Orthos Europe has been acquired by Atrium Innovations
Holland Venture has sold Orthos Europe to Atrium Innovations.
Orthos Europe’s main brand is AOV under which high-quality food supplements such as multi-vitamins, minerals, probiotics, enzymes, fatty acids and antioxidants are developed and marketed. The company was founded over 20 years ago and has a very strong position in the Netherlands, where it is a leading player in its market segment.
Atrium Innovations is a developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries. Atrium markets a portfolio of finished products through its sales and marketing network in more than 35 countries, primarily in North America and Europe.
Holland Venture is an independent private equity fund located in Amsterdam. Since 1981, Holland Venture has realized the growth potential of many of its investments and has proven to be a trustworthy partner.
Oaklins' team in the Netherlands advised the seller in this transaction.
Contacter l'équipe de la transaction
Maarten Wolleswinkel
Oaklins Netherlands
Transactions connexes
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
En apprendre plusEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
En apprendre plusOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
En apprendre plus